Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Prognostic communication, psychological distress, and caregiving burden among caregivers of patients with decompensated cirrhosis

Li L, Donlan J, Nurhussien L, Horick N, Zeng C, Indriolo T, Armstrong ME, Bizup G, Dalvi A, Zhu E, Diop MS, Mason N, Engel[...]

Amara Yad Image: The Relationship of the Pulmonary Artery to the Atrio-Caval Junction

Shivkumar K. Amara Yad Image: The Relationship of the Pulmonary Artery to the Atrio-Caval Junction. J Am Coll Cardiol. 2025 Oct 28;86(17):1456-1458. doi: 10.1016/j.jacc.2025.09.026. Epub[...]

Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement

Greenland JR, Perch M, Halloran K, Levine DJ, Morrell ED, Reed A, Shaver CM, Singer JP, Sweet SC, Vos R, Aryal S, Avdimiretz N, Burrows[...]